Second-line chemotherapy for refractory
โ
Maurie Markman
๐
Article
๐
1994
๐
John Wiley and Sons
๐
English
โ 568 KB
Over the past decade intraperitoneal therapy in the management of ovarian cancer has evolved from a pharmacokinetic concept into a rationale treatment strategy for a specific subset of patients with this disease. Patients with small-volume residual ovarian cancer (microscopic disease only or macrosc